2-FMA
2-fluoro-N-methylamphetamine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2-FMA (2-fluoromethamphetamine) is a synthetic stimulant of the phenethylamine class. It is a fluorinated structural analog of methamphetamine, distinguished by a cognitively focused, less euphoric profile. 2-FMA is presumed to be a monoamine releasing agent, producing its effects by driving dopamine and norepinephrine from nerve terminals into the synapse.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methamphetamine, other dopaminergic stimulants +1 moreamphetamine, methamphetamine, other dopaminergic stimulants, other fluorinated amphetamines show less
Ring-fluorinated amphetamine analogs appeared on illicit and gray markets in the early 2000s,[3] with the first systematic forensic characterization of the series published in 2005.[4] 2-FMA became available as a research chemical by approximately 2007–2010 and gained a reputation as a "functional" stimulant in online communities.[5] It remains unscheduled at the federal level in the United States but is explicitly controlled in Germany, Canada, and the United Kingdom.
Subjective effects include focus enhancement, wakefulness, motivation enhancement, appetite suppression, and increased heart rate. The experience is utilitarian — a clean, task-oriented sharpening of attention and drive without the rush or compulsive redosing characteristic of more recreational stimulants.[6] Anxiety, jaw tension, insomnia, and cardiovascular strain are common unsought effects.
Dependence potential is estimated as moderate by structural analogy to amphetamine, and no lethal dose or systematic toxicity data exist. Cardiovascular stress — elevated blood pressure, rapid heart rate, and vasoconstriction — is the primary acute risk, compounding with repeated use or high doses.[7][8] No controlled human study of any kind has been conducted; the current understanding rests on one rodent pharmacology study, a single forensic metabolite analysis, and community self-reports.[9]
History[edit]
History
Discovery
No specific inventor or institutional synthesis record for 2-FMA has been identified. The compound belongs to a family of ring-fluorinated amphetamine analogs that emerged from clandestine and commercial research chemical production rather than academic or pharmaceutical research. The first published analytical work on the fluoroamphetamine series — covering positional isomers and their N-methylated derivatives — appeared in 2005, establishing forensic reference standards for the group.[4]
Market appearance and forensic detection
2-FMA was available as a gray-market research chemical by approximately 2007, with broader online distribution from around 2010.[5] Italian forensic laboratories documented the compound among novel psychoactive substances seized from Internet purchases between 2013 and 2015.[10] A 2023 Japanese forensic case provided the only published human metabolic data.[3]
Research status
As of 2026, no clinical trials have been registered for 2-FMA. Published research is limited to forensic analytical characterization,[4][10] one human metabolite identification study,[3] and a single rodent pharmacology study examining locomotor and discriminative stimulus effects.[6] The compound has no therapeutic development history.
The name "2-FMA" follows standard research chemical nomenclature: the numeral indicates the ring position of the fluorine substituent, and FMA abbreviates fluoromethamphetamine. Among online communities, 2-FMA earned a reputation as the archetypal "functional stimulant" — valued less for recreation than for sustained productivity, a framing that distinguishes it from its positional isomer 4-FMA, which carries a more empathogenic, MDMA-adjacent reputation.
Chemistry[edit]
Chemistry
Structural class
2-FMA (1-(2-fluorophenyl)-N-methylpropan-2-amine) is a substituted amphetamine of the phenethylamine family. Its parent scaffold is methamphetamine, with a single fluorine atom at the ortho (2-) position of the phenyl ring. This places it in a series of ring-fluorinated methamphetamine analogs alongside 3-FMA (meta) and 4-FMA (para). The non-N-methylated counterpart is 2-fluoroamphetamine (2-FA).
The position of the fluorine atom matters pharmacologically. Para-halogen substitution on amphetamine significantly increases serotonin release potency relative to the unsubstituted parent — an effect demonstrated for 4-FMA but not characterized for the ortho position.[11] This structural difference likely accounts for 2-FMA's less empathogenic, more dopamine/norepinephrine-weighted profile compared to 4-FMA.
Molecular properties
| Molecular formula | C₁₀H₁₄FN |
| Molecular weight | 167.22 g/mol |
The fluorine atom introduces electron-withdrawing character to the aromatic ring and modestly increases lipophilicity relative to unsubstituted methamphetamine. The carbon–fluorine bond is among the strongest single bonds in organic chemistry (~485 kJ/mol), conferring metabolic resistance to oxidation at the substituted position.
Stereochemistry
2-FMA has one chirality center at the α-carbon, producing R(−) and S(+) enantiomers resolvable by chiral HPLC.[12] By analogy to methamphetamine, the S(+)-enantiomer is expected to be more pharmacologically active, but no enantioselective pharmacology study has been published. Commercial and illicit samples are understood to be racemic mixture.[13] citation needed
Physical properties
No peer-reviewed characterization of the free base or hydrochloride salt exists. Melting point, solubility, and stability data have not been formally reported. The free base is expected to be a liquid or low-melting solid based on analogy to methamphetamine. Research chemical vendors typically distribute 2-FMA as a crystalline hydrochloride powder. inferred
Pharmacology[edit]
Pharmacology
Mechanism of action
No published binding affinity or release potency data exist for 2-FMA at any molecular target. Its mechanism is inferred entirely from structural analogy to methamphetamine and the broader amphetamine class.
Amphetamine-type stimulants enter nerve terminals through dopamine and norepinephrine transporters, then reverse transporter direction, causing active release of stored dopamine and norepinephrine into the synapse.[1][2] They also displace monoamines from storage vesicles, amplifying this outward flow.
The ortho-fluorine substitution distinguishes 2-FMA from its para isomer 4-FMA, which shows significantly enhanced serotonin release — producing an MDMA-like mixed profile.[11] User reports consistently describe 2-FMA as less euphoric and less serotonergic than 4-FMA, consistent with a dopamine/norepinephrine-predominant mechanism.[5][14] This inference remains unverified by direct laboratory measurement. safety citation needed
In vivo pharmacology
The only animal study directly testing 2-FMA examined fluorinated amphetamine and methamphetamine analogs in rodent models.[6]
In locomotor assays, 2-FMA produced dose-dependent stimulation but was comparatively weak — roughly half the peak activity of methamphetamine-equivalent compounds like 2-FA and 3-FA. In discriminative stimulus tests, however, 2-FMA fully substituted for methamphetamine, meaning trained animals could not distinguish its internal effects from those of methamphetamine.
This dissociation — weak motor activation but full methamphetamine-like interoceptive effects — aligns with the community description of a stimulant that feels functional and focused without producing strong physical activation. Self-administration studies, the standard test for abuse potential, have not been conducted.
Pharmacokinetics
No human pharmacokinetic parameters have been measured — no plasma levels, half-life, bioavailability, or protein binding data exist.
The only published metabolic data come from a Japanese forensic case.[3] Three principal metabolic pathways were identified: N-hydroxylation (the primary characteristic metabolite), aliphatic hydroxylation to 2-fluoroephedrine, and N-demethylation to 2-fluoroamphetamine. This profile differs from methamphetamine, which primarily undergoes aromatic hydroxylation and N-demethylation.
Community-reported oral duration data — onset in 30–60 minutes, peak at 2.5–4 hours, total duration of 7–9 hours — are broadly consistent with the amphetamine class. The parent compound methamphetamine has a plasma half-life of approximately 11 hours.[15]
Neuroscience[edit]
Neuroscience
Where it acts
No neuroimaging or neurochemical studies have been conducted with 2-FMA. By class inference, amphetamine-type releasing agents potentiate dopamine signaling in two key circuits: the mesolimbic pathway (ventral tegmental area to nucleus accumbens), which drives motivation and reward, and the mesocortical pathway (to prefrontal cortex), which supports executive function, working memory, and sustained attention.[2]
2-FMA's weak locomotor stimulation in animal models despite full methamphetamine-like interoceptive effects[6] raises the possibility that it preferentially engages cortical over subcortical dopamine circuits — more prefrontal sharpening, less motor drive. This hypothesis has not been tested directly.
Why it matters
The "functional stimulant" profile maps onto a well-established model: catecholaminergic cognitive enhancement follows an inverted-U dose-response in the prefrontal cortex. Low-to-moderate dopamine and norepinephrine release optimizes executive function; excessive release impairs it. 2-FMA's reported productive window at common doses and cognitive deterioration at high doses fits this curve.
Chronic amphetamine exposure produces neuroadaptive changes — transporter upregulation, downregulation, and depleted baseline dopamine — underlying both tolerance and the flat, anhedonic state reported during withdrawal. Whether 2-FMA produces equivalent changes at equivalent exposures is unknown.
Key unanswered questions include whether 2-FMA preferentially releases dopamine in cortical versus subcortical circuits (explaining its cognitive-over-motor profile), what its actual SERT activity is (and how ortho-fluorine substitution modifies it compared to para substitution), and whether chronic use produces the same dopaminergic depletion and receptor changes documented for methamphetamine.
Subjective Effects[edit]
Subjective Effects
2-FMA produces a stimulant experience defined by cognitive clarity rather than euphoric intensity. Users describe a state of sustained, directed attention — task completion feels easier, mental endurance extends, and motivation sharpens without the restless energy or compulsive redosing typical of more recreational amphetamines. At low doses, the shift is subtle and utilitarian; at higher doses, physical stimulation becomes more prominent and the cognitive advantage narrows as overstimulation sets in. The experience is relatively insensitive to setting — it reads as a productivity tool rather than a mood-altering event.
Within the amphetamine class, 2-FMA sits closest to lisdexamfetamine in community comparisons: moderate duration, cognitively weighted, and low in acute reinforcement. It lacks the empathogenic warmth of its positional isomer 4-FMA, which carries serotonergic qualities that give it an MDMA-adjacent character.[11]
Effect Grid
The core functional stimulant profile — sustained focus enhancement, motivation, clear-headed wakefulness, and productive task engagement. Thought acceleration and thought organization are prominent. Cognitive euphoria is present but moderate, described as less intense than d-amphetamine or methamphetamine. Community sources frequently compare this dose range to lisdexamfetamine (Vyvanse) in character.
Moderate appetite suppression, mild cardiovascular activation (elevated heart rate, mild vasoconstriction), and dry mouth. Pupil dilation may be noticeable. Restlessness can emerge toward the offset phase. Bruxism and sweating are generally absent or mild at this level.
This is the most frequently reported "functional" dose range. Sleep disruption extends well beyond subjective stimulation offset — wakefulness typically persists 8–10 hours even after core effects have declined. Plan accordingly.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Auditory enhancement · Sound sensitivity · Sleep-transition hallucinations · Visual acuity enhancement · Brightness alteration · Tinnitus · Object transformations
Brightness alteration · Tinnitus · Object transformations
Pupil dilation · Insomnia · Dry mouth · Physical fatigue · Excessive sweating · Restlessness · Dehydration sensation · Body high · Heart rate perception changes · Muscle tension · Nasal congestion · Abnormal heartbeat · Respiratory stimulation · Bodily lightness · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Nausea · Bruxism · Sexual arousal suppression · Sexual arousal enhancement · Headache · Sedation · Spontaneous body sensations · Trembling · Tactile euphoria · Increased urination · Breathing alteration · Dizziness · Vomiting
Physical fatigue · Excessive sweating · Restlessness · Dehydration sensation · Body high · Heart rate perception changes · Muscle tension · Nasal congestion · Respiratory stimulation · Bodily lightness · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Nausea · Bruxism · Sexual arousal suppression · Sexual arousal enhancement · Headache · Sedation · Spontaneous body sensations · Trembling · Tactile euphoria · Increased urination · Breathing alteration · Dizziness · Vomiting
Motivation enhancement · Immersion enhancement · Analysis enhancement · Thought organization · Information processing enhancement · Cognitive fatigue · Aesthetic enhancement · Cognitive flexibility · Conceptual thinking · Memory enhancement · Novelty enhancement · Creativity enhancement · Language enhancement · Motivation suppression · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Thought deceleration · Memory suppression · Cognitive dysphoria · Cognitive impairment · Multiple thought streams · Thought loops · Creativity suppression · Focus suppression · Thought disorganization · Delusions
Thought organization · Information processing enhancement · Cognitive fatigue · Aesthetic enhancement · Cognitive flexibility · Conceptual thinking · Memory enhancement · Novelty enhancement · Creativity enhancement · Language enhancement · Motivation suppression · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Thought deceleration · Memory suppression · Cognitive dysphoria · Cognitive impairment · Multiple thought streams · Thought loops · Creativity suppression · Focus suppression · Thought disorganization
Emotional suppression · Anhedonia · Dysphoria · Emotional lability · Empathy enhancement · Mania
Emotional lability · Empathy enhancement
Craving · Flow state · Sociability enhancement · Self-control enhancement · Disinhibition · Social connection · Sociability suppression · Social disconnection · Depersonalization · Derealization
Disinhibition · Social connection · Sociability suppression · Social disconnection · Depersonalization · Derealization
Timeline
Gradual emergence of alertness and mild cognitive sharpening; minimal physical effects. A subtle increase in wakefulness becomes perceptible.
Progressive build of focus, motivation, and wakefulness. Mild appetite suppression begins. Task engagement increases noticeably.
Full functional stimulant profile — sustained focus enhancement, motivation, clear-headed wakefulness, moderate appetite suppression, mild cardiovascular activation. Thought organization and analysis enhancement are prominent.
Gradual decline in cognitive enhancement and motivation. Residual wakefulness persists well after subjective stimulation fades. Appetite begins returning; mild cognitive fatigue may emerge.
Wakefulness and mild restlessness persist after core effects have resolved. Potential for insomnia, mild irritability, and physical fatigue.
⚠ Avoid driving or operating machinery until a full sleep cycle has been completed.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · other dopaminergic stimulants
Toxicity
No lethal dose, systematic toxicity study, or published overdose case report exists for 2-FMA in any species. All toxicity assessment relies on class inference from methamphetamine and the broader amphetamine family. The fluorinated amphetamine class is associated with heart failure, cerebral hemorrhage, and death in emergency department reports.[6]
Heart and circulation
Cardiovascular toxicity is the primary physical danger. By structural analogy to methamphetamine, 2-FMA carries dose-dependent risk of elevated blood pressure, rapid heart rate, and vasoconstriction.[7][8] At high doses or with chronic exposure, these effects may escalate to dangerous heart rhythms, vasospasm, acute coronary events, or cerebral hemorrhage.
The sympathomimetic overdose picture includes dilated pupils, tremor, agitation, overactive reflexes, seizures, and dangerously elevated body temperature.[16] inferred
Detection limitations
Standard amphetamine urine screens are unlikely to detect 2-FMA.[9] In an emergency room, this means 2-FMA toxicity may go unrecognized without specialized laboratory analysis. Recommended forensic markers are N-OH-2-FMA and 2-fluoroephedrine.[3] Standard analytical methods cannot reliably distinguish 2-FMA from its positional isomers (3-FMA, 4-FMA) without advanced techniques.[4]
Psychological risks
No controlled data on psychological adverse effects exist. By class inference:
Acute risks: anxiety, agitation, insomnia, and paranoia can emerge at higher doses or with repeated dosing in a single session. Community reports describe excessive stimulation and anxious thought patterns above 50 mg oral.[5]
Psychosis: Amphetamine-induced psychosis — paranoid delusions, auditory hallucinations, agitation — is a well-documented phenomenon, typically triggered by high doses or sustained use.[17] 2-FMA's full substitution for methamphetamine in animal discrimination tests suggests this risk applies.[6]
Chronic use: Sustained daily stimulant use is associated with cognitive impairment, emotional flattening, anhedonia, and depressive symptoms during both active use and withdrawal.
Tolerance and dependence
No 2-FMA-specific data exist. The following is class-level inference.
Tolerance develops with repeated use as the brain adjusts its dopamine system — transporters upregulate, receptors downregulate, and baseline dopamine depletes. Community estimates suggest a tolerance half-life of approximately 5 days and full reset within 1.5 weeks.[5] Cross-tolerance occurs with other dopaminergic stimulants. safety citation needed
Dependence potential is estimated as moderate. Animal data show abuse potential comparable to methamphetamine based on discriminative stimulus substitution, though weaker locomotor effects may attenuate acute reinforcement.[6] Self-administration studies have not been conducted. safety citation needed
Withdrawal after chronic use is expected to produce fatigue, excessive sleep, low mood, anhedonia, appetite enhancement, and cognitive difficulty.[18] Pharmacological options for amphetamine-class withdrawal remain limited; mirtazapine, naltrexone, and bupropion have shown preliminary benefit for methamphetamine withdrawal.[18]
Drug interactions
No 2-FMA-specific interaction data exist. All assessments are based on mechanism and class inference. safety citation needed
MAO inhibitors represent the most dangerous combination. Concurrent use with any amphetamine-type releaser risks severe blood pressure crisis and potentially fatal serotonin syndrome. This combination is considered life-threatening.
Serotonergic agents: The risk of serotonin syndrome depends on 2-FMA's uncharacterized serotonin release potency. Tramadol poses dual danger: additive serotonergic effects and additive cardiovascular strain. This combination is classified as potentially lethal in harm-reduction databases.
Dissociatives: Combination with PCP or related compounds introduces unpredictable effects including dangerously elevated body temperature, lowered seizure threshold, and cardiovascular instability.
Other stimulants: Co-administration with cocaine or other stimulants compounds cardiovascular risk — additive blood pressure elevation, rapid heart rate, and vessel constriction.
CNS depressants: Combination with alcohol, GHB/GBL, or opioids may mask depressant effects during stimulant activity, with risk of respiratory depression emerging as the stimulant wears off.
Contraindications
No 2-FMA-specific contraindication data exist. The following are derived from the amphetamine class. inferred
Absolute:
- MAO inhibitor use: Risk of fatal blood pressure crisis and serotonin toxicity.
- Severe heart conditions: Including uncontrolled high blood pressure, coronary artery disease, recent heart attack, cerebrovascular disease, and aortic stenosis.
Relative:
- History of psychosis or schizophrenia: Amphetamine-type stimulants can trigger or worsen psychotic episodes.[17]
- Seizure disorders: Stimulants may lower seizure threshold.
- Overactive thyroid: Additive sympathomimetic effects.
- Glaucoma: pupil dilation from stimulant activity may trigger angle-closure crisis.
- Pregnancy and breastfeeding: Amphetamine-class compounds cross the placental barrier; no reproductive safety data exist for 2-FMA.
Harm Reduction[edit]
Forms & Identification
2-FMA circulates as an unregulated research chemical with no manufacturing standards. Batch purity varies unpredictably, and the compound cannot be visually distinguished from its positional isomers 3-FMA and 4-FMA — which have different pharmacological profiles (4-FMA is notably more serotonergic). Standard amphetamine immunoassay tests will not detect 2-FMA,[9] and standard analytical methods cannot reliably distinguish it from other fluoromethamphetamine isomers without advanced techniques.[4]
Reagent testing provides partial identification but cannot confirm purity or rule out all adulterants. For a substance active at single-digit milligram doses, accurate weighing with a milligram-precision scale is non-negotiable — visual estimation of powder is dangerously imprecise at this potency range.
Guidelines
- Test every batch with reagent kits before use. Reagent results narrow the possibilities but do not confirm identity — consider sending a sample to a drug checking service if available.
- Weigh every dose on a milligram-precision scale (0.001g). Do not estimate by eye.
- Start low. First-time users or new batches warrant a threshold dose (5–10 mg oral) to assess individual response and batch potency.
- Oral is the lower-risk route. Insufflation produces faster onset and higher peak concentrations, increasing cardiovascular strain and redosing temptation.
- Avoid redosing. The long duration means effects from a second dose stack on the first. If the initial dose feels insufficient after 90 minutes, the session is unlikely to improve with more.
- Set a hard stop time. Decide before dosing when the session ends. Stimulant-driven focus makes it easy to keep working well past the point of diminishing returns.
- Eat before dosing and have food accessible. Appetite suppression can last the full duration.
- Hydrate steadily but do not force excessive water intake.
Set & Setting
2-FMA is primarily used as a productivity tool rather than a recreational substance. A familiar, comfortable environment — typically a workspace or home — suits the experience better than social or novel settings. Because the duration extends to 7–9 hours, timing matters: dosing in the afternoon risks insomnia into the early morning hours.
Physical state is a factor. Cardiovascular baseline matters — users with elevated resting heart rate, high blood pressure, or recent stimulant use carry additional risk. Adequate hydration and recent food intake before dosing help manage the appetite suppression and mild dehydration that accompany stimulant use.
Aftercare & integration. The stimulant comedown from 2-FMA is typically mild compared to more euphoric amphetamines but compounds with repeated use. Priority after a session: sleep, food, and rest.
Sleep recovery: Insomnia is common, especially with afternoon dosing. Avoid compensating with depressants or sedatives. Melatonin or a dark, quiet environment may help. Allow a full night of unrestricted sleep.
Nutrition: Appetite suppression may persist for several hours after the stimulant effects fade. Calorie-dense, easy-to-eat foods help replenish what was missed during the session.
Psychological reset: Repeated stimulant use can create a pattern where productive days require a dose and rest days feel flat. Pay attention to whether the substance is becoming a condition for normal function rather than an occasional tool.
Recovery & Support
Stimulant dependence often develops gradually — 2-FMA's "functional" framing can mask escalating use because the substance is associated with productivity rather than intoxication. Warning signs include inability to work without dosing, dose escalation, continued use despite cardiovascular symptoms, and withdrawal-driven low mood or fatigue.
Amphetamine-class withdrawal is not medically dangerous but can be psychologically difficult: fatigue, anhedonia, and cognitive fog may persist for days to weeks.[18] Professional support options include outpatient addiction counseling, cognitive behavioral therapy, and peer support groups such as SMART Recovery. Pharmacological management options remain limited; mirtazapine, naltrexone, and bupropion have shown preliminary benefit for methamphetamine withdrawal and may be relevant.[18]
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable but manageable effects include mild anxiety, jitteriness, and rapid heartbeat. Seek immediate medical help if any of the following occur:
- Chest pain or pressure
- Severe headache with sudden onset (possible blood pressure crisis)
- Seizure or loss of consciousness
- Body temperature hot to the touch through clothing
- Extreme confusion, paranoia, or aggression that cannot be redirected
- Breathing difficulty
Immediate steps:
- 1. Call emergency services if any of the above signs are present.
- 2. Move the person to a cool, quiet space. Remove excess clothing if overheating.
- 3. Do not restrain them unless they are in immediate physical danger.
- 4. Do not give other substances to "counteract" the stimulant.
- 5. Stay with the person until help arrives. Monitor breathing and consciousness.
What to tell the dispatcher:
State that the person has taken a stimulant (specify "fluorinated amphetamine structural analog" or "2-FMA" if known), the approximate amount, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
No specific reversal agent exists for amphetamine-type stimulant toxicity. Hospital management is supportive: cooling, sedation with benzodiazepines, and blood pressure control.
Legal Status[edit]
Legal Status
As of 2026, 2-FMA occupies an inconsistent legal position across jurisdictions. It is explicitly controlled in several countries while remaining unscheduled at the federal level in the United States, where it may nonetheless be prosecutable under structural analog provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. Potentially prosecutable under the Federal Analogue Act (21 U.S.C. §813) if sold for human consumption with intent to produce effects substantially similar to a Schedule I or II substance[19] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled as an amphetamine analogue; maximum penalties include life imprisonment for supply[19] |
| Germany | Anlage I (BtMG) | Controlled since December 13, 2014; manufacture, possession, and import/export without license punishable by fine or up to 5 years imprisonment[13] |
| Canada | Schedule I (CDSA) | Controlled since 1996 as an analog of methamphetamine[19] |
| China | Controlled substance | Listed October 2015[19] |
| Ukraine | Narcotic | Controlled since July 2019[19] |
| Australia | Not specifically confirmed | No specific scheduling identified; analog provisions may applycitation needed |
Analog act considerations
In the United States, 2-FMA's structural relationship to methamphetamine (a Schedule II controlled substance) places it within the scope of the Federal Analogue Act, which treats substances "substantially similar" in structure and effect to listed substances as Schedule I — provided they are intended for human consumption. The full discriminative stimulus substitution for methamphetamine demonstrated in rodent studies[6] could constitute pharmacological evidence of substantial similarity in a prosecution.
references
- [1] ^abSimmler LD, Liechti ME (2018) Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_113
- [2] ^abcLuethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
- [3]
- [4]
- [5]
- [6]